材料科学-7概要.ppt

策 略 学科交叉融合角度构思生物医用材料，形成学科交叉平台； 增加开放度，加强国内外的合作； 严格遵照SFDA生物医用材料的法规与标准； 分阶段实施产品商品化，以缓减投入风险； 传统中药与具有生物活性的生物医用材料结合，形成富有特色且具有自主知识产权的生物材料产业； 加强产-学-研合作。 再 见！ * * * * * * To address the varied challenges in oral delivery of numerous promising compounds — including poor aqueous solubility, poor absorption and large molecular size — ALZA offers a number of technological alternatives. From our well-established, rate-controlled systems to the newest approaches, this technology is bolstered by ALZAs extensive knowledge base in oral drug delivery and commercial product experience. * The DUROS? implant is a miniature cylinder made from a titanium alloy, which protects and stabilizes the drug inside, using ALZAs proprietary formulation technology. Water enters into one end of the cylinder through a semipermeable membrane; the drug is delivered from a port at the other end of the cylinder at a controlled rate appropriate to the specific therapeutic agent. * ALZA Corporation has taken its leadership position in transdermal research and development to a new level with its latest innovation: Macroflux? transdermal technology. Macroflux? systems can be drug-coated for direct administration or can be used in combination with passive transdermal or electrotransport systems to significantly expand the delivery opportunities for synthetic drugs, therapeutic proteins and vaccines. Macroflux? transdermal technology incorporates a thin titanium screen with precision microprojections that, when applied to the skin, creates superficial pathways through the skins dead barrier layer allowing transport of macromolecules. Macroflux? technology provides the option of dry-coating the drug on the Macroflux? microprojection array for bolus delivery into the skin or using a drug reservoir for continuous passive or electrotransport applications. In addition, the creation of Macroflux? pathways allows for better control of drug distribution throughout the skin patch treatment area and reduction in p